biostudies-literatureRocco PRMConselho Nacional de Desenvolvimento Científico e Tecnológico2003725https://www.ebi.ac.uk/biostudies/studies/S-EPMC7758778biostudies-literatureUnknown58(1)<h4>Background</h4>Nitazoxanide is widely available and exerts broad-spectrum antiviral activity <i>in vitro</i>. However, there is no evidence of its impact on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.<h4>Methods</h4>In a multicentre, randomised, double-blind, placebo-controlled trial, adult patients presenting up to 3 days after onset of coronavirus disease 2019 (COVID-19) symptoms (dry cough, fever and/or fatigue) were enrolled. After confirmation of SARS-CoV-2 infection using reverse transcriptase PCR on a nasopharyngeal swab, patients were randomised 1:1 to receive either nitazoxanide (500 mg) or placebo, three times daily, for 5 days. The primary outcome was complete resolution of symptoms. Secondary outcomes were viral load, laboratory tests, serum biomThe European respiratory journalEarly use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial.PMC7758778403485/2020-7de Carvalho AFFernandes APSMPaes NFLuiz RRCordeiro ATMaciel PVMProenca-Modena JLDos Santos ISPelosi PRocco PRMGoncalves JMJAlves PAMarques RETierno PFGMMRocha RPLapa E Silva JRJunior WFCarbonieri MNMelo-Junior MACDe Oliveira LFGLima CCDos Santos EACruz FFMagri Ede Moraes NFSARITA-2 investigatorsMoura MAFranchini KGSilva PLTrivella DBBfalseEarly use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial.<h4>Background</h4>Nitazoxanide is widely available and exerts broad-spectrum antiviral activity <i>in vitro</i>. However, there is no evidence of its impact on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.<h4>Methods</h4>In a multicentre, randomised, double-blind, placebo-controlled trial, adult patients presenting up to 3 days after onset of coronavirus disease 2019 (COVID-19) symptoms (dry cough, fever and/or fatigue) were enrolled. After confirmation of SARS-CoV-2 infection using reverse transcriptase PCR on a nasopharyngeal swab, patients were randomised 1:1 to receive either nitazoxanide (500 mg) or placebo, three times daily, for 5 days. The primary outcome was complete resolution of symptoms. Secondary outcomes were viral load, laboratory tests, serum biom2021-01-01T00:00:00Z2021 Jul2026-06-06T22:57:09.934Z2021-02-21T04:09:26ZS-EPMC77587783336110010.1183/13993003.03725-2020